Workflow
Cocrystal(COCP)
icon
Search documents
Cocrystal Pharma (COCP) Investor Presentation - Slideshow
2020-04-24 15:03
Collaboration and Financials - Cocrystal recognized revenue of $6560000 in 2019 from the Merck collaboration and is eligible for up to $156 million in milestone payments and royalties[8] - As of January 31, 2020, Cocrystal had 52100000 common shares outstanding[59] - As of January 31, 2020, Cocrystal's fully diluted shares outstanding were 53307139[58] - As of December 31, 2019, Cocrystal had a cash balance of approximately $7400000[59] Hepatitis C (HCV) Program - In a Phase 2a study, 67% of subjects (8 out of 12) achieved both SVR12 and SVR24, considered a virologic cure, with a 6-week treatment regimen[29] - CC-31244 demonstrated a viral load decline of 3 logs by 48 hours in HCV GT1 subjects during Phase 1b data[22] - Approximately 71 million people are infected with Hepatitis C globally[15] - Only 2% of infected Hepatitis C patients are being treated[17] Influenza Program - The global influenza market was valued at nearly $5600000000 in 2017 and is expected to reach nearly $6500000000 by 2022[34] - Influenza causes 1 billion cases annually[34] - Influenza results in up to 650000 deaths worldwide annually[35] Coronavirus (COVID-19) Program - Cocrystal expects to initiate preclinical studies of COVID-19 inhibitors in H2 2020[11] - Cocrystal acquired exclusive patent rights and know-how for coronavirus therapeutics for human use from Kansas State University Research Foundation (KSURF)[9]
Cocrystal(COCP) - 2019 Q4 - Annual Report
2020-03-27 20:31
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of Each Class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share COCP The Nasdaq Stock Market LLC (The Nasdaq Capital Market) Large accelerated filer [ ] Accelerated filer [ ] Non-accelerated filer [X] Smaller reporting company [X] Emerging growth company [ ] FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended ...
Cocrystal(COCP) - 2019 Q3 - Quarterly Report
2019-11-12 13:31
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Large accelerated filer [ ] Accelerated filer [X] Non-accelerated filer [ ] Smaller reporting company [X] Emerging growth company [ ] Title of Each Class Trading Symbol(s) Name of each exchange on which registered Common Stock COCP The Nasdaq Stock Market LLC (The Nasdaq Capital Market) FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 ...
Cocrystal(COCP) - 2019 Q2 - Quarterly Report
2019-08-09 12:01
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Large accelerated filer [ ] Accelerated filer [X] Non-accelerated filer [ ] Smaller reporting company [X] Emerging growth company [ ] Title of Each Class Trading Symbol(s) Name of each exchange on which registered Common Stock COCP The Nasdaq Stock Market LLC (The Nasdaq Capital Market) FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR [ ...
Cocrystal(COCP) - 2019 Q1 - Quarterly Report
2019-05-10 12:31
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Large accelerated filer [ ] Accelerated filer [X] Non-accelerated filer [ ] Smaller reporting company [X] Emerging growth company [ ] Title of Each Class Trading Symbol(s) Name of each exchange on which registered Common Stock COCP The Nasdaq Stock Market LLC (The Nasdaq Capital Market) FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR [ ...
Cocrystal(COCP) - 2018 Q4 - Annual Report
2019-04-01 12:31
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2018 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 000-55158 Cocrystal Pharma, Inc. | --- | --- | |--------------------------------------------------------------------------------------------------|----------------------------- ...